within Pharmacolibrary.Drugs.ATC.N;

model N03AX27
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 1.5e-05,
    adminDuration  = 600,
    adminMass      = 1500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0016,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 60
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N03AX27</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ganaxolone is a synthetic neuroactive steroid and positive allosteric modulator of GABA-A receptors. It is developed and approved as an anticonvulsant medication for the treatment of seizures, particularly in rare epilepsy syndromes such as CDKL5 deficiency disorder. Ganaxolone acts by enhancing inhibitory neurotransmission in the central nervous system.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic data following oral administration in healthy adult volunteers and patients with refractory epilepsy.</p><h4>References</h4><ol><li><p> (2024). Comparison Table: Some oral antiseizure medications. <i>The Medical letter on drugs and therapeutics</i> 66(1708) e133–e140. DOI:<a href=\"https://doi.org/10.58347/tml.2024.1708b\">10.58347/tml.2024.1708b</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39073881/\">https://pubmed.ncbi.nlm.nih.gov/39073881</a></p></li><li><p>Gould, A, &amp; Amin, S (2024). An overview of ganaxolone as a treatment for seizures associated with cyclin-dependent kinase-like 5 deficiency disorder. <i>Expert review of neurotherapeutics</i> 24(10) 945–951. DOI:<a href=\"https://doi.org/10.1080/14737175.2024.2385937\">10.1080/14737175.2024.2385937</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39082513/\">https://pubmed.ncbi.nlm.nih.gov/39082513</a></p></li><li><p>Fitch, WL, et al., &amp; Baillie, TA (2023). Complex Metabolism of the Novel Neurosteroid, Ganaxolone, in Humans: A Unique Challenge for Metabolites in Safety Testing Assessment. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 51(6) 753–763. DOI:<a href=\"https://doi.org/10.1124/dmd.122.001218\">10.1124/dmd.122.001218</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36863866/\">https://pubmed.ncbi.nlm.nih.gov/36863866</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N03AX27;
